FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387303723> ?p ?o ?g. }

• W4387303723 abstract "Introduction Online adaptive magnetic resonance-guided radiotherapy (MRgRT) is a promising treatment modality for pancreatic cancer and is being employed by an increasing number of centers worldwide. However, clinical outcomes have only been reported on a small scale, often from single institutes and in the context of clinical trials, in which strict patient selection might limit generalizability of outcomes. This study presents clinical outcomes of a large, international cohort of patients with (peri)pancreatic tumors treated with online adaptive MRgRT. Methods We evaluated clinical outcomes and treatment details of patients with (peri)pancreatic tumors treated on a 1.5 Tesla (T) MR-linac in two large-volume treatment centers participating in the prospective MOMENTUM cohort (NCT04075305). Treatments were evaluated through schematics, dosage, delivery strategies, and success rates. Acute toxicity was assessed until 3 months after MRgRT started, and late toxicity from 3–12 months of follow-up (FU). The EORTC QLQ-C30 questionnaire was used to evaluate the quality of life (QoL) at baseline and 3 months of FU. Furthermore, we used the Kaplan–Meier analysis to calculate the cumulative overall survival. Results A total of 80 patients were assessed with a median FU of 8 months (range 1–39 months). There were 34 patients who had an unresectable primary tumor or were medically inoperable, 29 who had an isolated local recurrence, and 17 who had an oligometastasis. A total of 357 of the 358 fractions from all hypofractionated schemes were delivered as planned. Grade 3–4 acute toxicity occurred in 3 of 59 patients (5%) with hypofractionated MRgRT and grade 3–4 late toxicity in 5 of 41 patients (12%). Six patients died within 3 months after MRgRT; in one of these patients, RT attribution could not be ruled out as cause of death. The QLQ-C30 global health status remained stable from baseline to 3 months FU (70.5 at baseline, median change of +2.7 [P = 0.5]). The 1-year cumulative overall survival for the entire cohort was 67%, and that for the primary tumor group was 66%. Conclusion Online adaptive MRgRT for (peri)pancreatic tumors on a 1.5 T MR-Linac could be delivered as planned, with low numbers of missed fractions. In addition, treatments were associated with limited grade 3–4 toxicity and a stable QoL at 3 months of FU." @default.
• W4387303723 created "2023-10-04" @default.
• W4387303723 creator A5006174923 @default.
• W4387303723 creator A5009834418 @default.
• W4387303723 creator A5011387566 @default.
• W4387303723 creator A5021970576 @default.
• W4387303723 creator A5028860020 @default.
• W4387303723 creator A5041449694 @default.
• W4387303723 creator A5042551389 @default.
• W4387303723 creator A5043777487 @default.
• W4387303723 creator A5065993006 @default.
• W4387303723 creator A5067310306 @default.
• W4387303723 creator A5071798797 @default.
• W4387303723 creator A5072899975 @default.
• W4387303723 creator A5074190717 @default.
• W4387303723 creator A5074625767 @default.
• W4387303723 date "2023-10-03" @default.
• W4387303723 modified "2023-10-05" @default.
• W4387303723 title "Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac" @default.
• W4387303723 cites W1563283949 @default.
• W4387303723 cites W1995087795 @default.
• W4387303723 cites W2019607817 @default.
• W4387303723 cites W2088735383 @default.
• W4387303723 cites W2101345979 @default.
• W4387303723 cites W2118797060 @default.
• W4387303723 cites W2165948908 @default.
• W4387303723 cites W2196287118 @default.
• W4387303723 cites W2568664803 @default.
• W4387303723 cites W2602228104 @default.
• W4387303723 cites W2604506868 @default.
• W4387303723 cites W2763991661 @default.
• W4387303723 cites W2903623792 @default.
• W4387303723 cites W2905949269 @default.
• W4387303723 cites W2930910485 @default.
• W4387303723 cites W2932433038 @default.
• W4387303723 cites W2947439377 @default.
• W4387303723 cites W2948795598 @default.
• W4387303723 cites W2972083722 @default.
• W4387303723 cites W2989786100 @default.
• W4387303723 cites W3005719787 @default.
• W4387303723 cites W3037453845 @default.
• W4387303723 cites W3039996279 @default.
• W4387303723 cites W3083705298 @default.
• W4387303723 cites W3085058587 @default.
• W4387303723 cites W3135350757 @default.
• W4387303723 cites W3160128359 @default.
• W4387303723 cites W3177518039 @default.
• W4387303723 cites W3204679501 @default.
• W4387303723 cites W4226153315 @default.
• W4387303723 cites W4226457995 @default.
• W4387303723 cites W4247785462 @default.
• W4387303723 cites W4308739453 @default.
• W4387303723 cites W4323981660 @default.
• W4387303723 doi "https://doi.org/10.3389/fonc.2023.1040673" @default.
• W4387303723 hasPublicationYear "2023" @default.
• W4387303723 type Work @default.
• W4387303723 citedByCount "0" @default.
• W4387303723 crossrefType "journal-article" @default.
• W4387303723 hasAuthorship W4387303723A5006174923 @default.
• W4387303723 hasAuthorship W4387303723A5009834418 @default.
• W4387303723 hasAuthorship W4387303723A5011387566 @default.
• W4387303723 hasAuthorship W4387303723A5021970576 @default.
• W4387303723 hasAuthorship W4387303723A5028860020 @default.
• W4387303723 hasAuthorship W4387303723A5041449694 @default.
• W4387303723 hasAuthorship W4387303723A5042551389 @default.
• W4387303723 hasAuthorship W4387303723A5043777487 @default.
• W4387303723 hasAuthorship W4387303723A5065993006 @default.
• W4387303723 hasAuthorship W4387303723A5067310306 @default.
• W4387303723 hasAuthorship W4387303723A5071798797 @default.
• W4387303723 hasAuthorship W4387303723A5072899975 @default.
• W4387303723 hasAuthorship W4387303723A5074190717 @default.
• W4387303723 hasAuthorship W4387303723A5074625767 @default.
• W4387303723 hasBestOaLocation W43873037231 @default.
• W4387303723 hasConcept C121608353 @default.
• W4387303723 hasConcept C126322002 @default.
• W4387303723 hasConcept C126838900 @default.
• W4387303723 hasConcept C143998085 @default.
• W4387303723 hasConcept C151730666 @default.
• W4387303723 hasConcept C188816634 @default.
• W4387303723 hasConcept C2779343474 @default.
• W4387303723 hasConcept C2780210213 @default.
• W4387303723 hasConcept C2989005 @default.
• W4387303723 hasConcept C509974204 @default.
• W4387303723 hasConcept C535046627 @default.
• W4387303723 hasConcept C71924100 @default.
• W4387303723 hasConcept C72563966 @default.
• W4387303723 hasConcept C86803240 @default.
• W4387303723 hasConceptScore W4387303723C121608353 @default.
• W4387303723 hasConceptScore W4387303723C126322002 @default.
• W4387303723 hasConceptScore W4387303723C126838900 @default.
• W4387303723 hasConceptScore W4387303723C143998085 @default.
• W4387303723 hasConceptScore W4387303723C151730666 @default.
• W4387303723 hasConceptScore W4387303723C188816634 @default.
• W4387303723 hasConceptScore W4387303723C2779343474 @default.
• W4387303723 hasConceptScore W4387303723C2780210213 @default.
• W4387303723 hasConceptScore W4387303723C2989005 @default.
• W4387303723 hasConceptScore W4387303723C509974204 @default.
• W4387303723 hasConceptScore W4387303723C535046627 @default.
• W4387303723 hasConceptScore W4387303723C71924100 @default.
• W4387303723 hasConceptScore W4387303723C72563966 @default.

• next